PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

NCT ID: NCT06089083

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

225 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-18

Study Completion Date

2033-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. Assess the risk factors associated with frailty in newly diagnosed gynecologic cancer participants.

SECONDARY OBJECTIVES:

I. Compare primary quality of life endpoint of "healthy days at home" between non-frail and frail participants (primary quality of life endpoint).

II. Compare other perioperative, oncologic, and quality of life outcomes between non-frail and frail participants.

OUTLINE: This is an observational study.

All new patients being evaluated for a new diagnosis of gynecologic cancer by the University of California, San Francisco (UCSF) Gynecologic Oncology service and the Dana-Farber Cancer Institute will be recruited in both the outpatient or inpatient setting. Study participants will be enrolled at the time of diagnosis and followed for up to one year after undergoing surgery for cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Female Reproductive System Neoplasm Gynecologic Cancer Gynecologic Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newly diagnosed gynecologic cancer

Participants will undergo physical function assessments, complete surveys, and medical records every 3 months +/- 4 weeks prior to standard of care surgery (outside of this protocol). After surgery subjects will be followed for at least 3 months +/- 4 weeks for up to one year after diagnosis. Medical record reviews will occur periodically to examine for long-term follow up oncologic outcomes of progression free survival, overall survival, and chemotherapy delays for up to 10 years after enrollment.

Physical function assessment

Intervention Type OTHER

Physical assessments of frailty will be conducted in person.

Self-reported Assessments and Questionnaires

Intervention Type OTHER

Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study

Surgery (Standard of Care, Non-Interventional)

Intervention Type PROCEDURE

Surgical data will be reviewed via medical record

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physical function assessment

Physical assessments of frailty will be conducted in person.

Intervention Type OTHER

Self-reported Assessments and Questionnaires

Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study

Intervention Type OTHER

Surgery (Standard of Care, Non-Interventional)

Surgical data will be reviewed via medical record

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Questionnaires Surgical Procedure

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or greater
* Undergoing evaluation for a newly diagnosed gynecologic malignancy
* Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria

* Contraindication to any study-related procedure or assessment
* Does not speak a language for which the consent form and study materials are available
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Conquer Cancer Foundation

OTHER

Sponsor Role collaborator

American Society of Clinical Oncology

OTHER

Sponsor Role collaborator

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephanie Cham, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, San Francisco

San Francisco, California, United States

Site Status RECRUITING

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Janet Titzler

Role: CONTACT

415-353-9600

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Janet Titzler

Role: primary

415-353-9600

Role: backup

877-827-3222

Alexi Wright, MD, MPH

Role: primary

617-632-2334

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2023-07434

Identifier Type: REGISTRY

Identifier Source: secondary_id

R03AG088902

Identifier Type: NIH

Identifier Source: secondary_id

View Link

K12HD001262

Identifier Type: NIH

Identifier Source: secondary_id

View Link

23407

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.